Enjaymo

Sutimlimab-jome (Enjaymo) is a monoclonal antibody that inhibits the classical complement pathway by binding to complement protein component 1 subcomponent s (C1s). This inhibition ultimately prevents hemolysis in patients with cold agglutinin disease (CAD). Sutimlimab-jome (Enjaymo) is FDA-approved for the treatment of hemolysis in adults with cold agglutinin disease (CAD). FDA approval: Indicated for treatment of hemolysis in adults with CAD (02/2022; revised PI 02/2024). Mechanism: Targets C1s, preventing C3 activation and subsequent extravascular hemolysis. Clinical trials (CARDINAL, CADENZA): demonstrated rapid increase in hemoglobin, reduction in transfusion needs, and improvement in fatigue scores. Special notes: Vaccination against encapsulated bacteria (pneumococcal, meningococcal, Hib) required before initiation. <a id="